In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 54 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Are we paying adequate attention to HDL cholesterol?

Session Poster Session 2

Speaker Andrea Velez Salas

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2019

  • Topic : preventive cardiology
  • Sub-topic : Secondary Prevention
  • Session type : Poster Session

Authors : A Velez Salas (Madrid,ES), LA Martinez Marin (Madrid,ES), R Dalmau Gonzalez-Gallarza (Madrid,ES), A Rivas Perez (Madrid,ES), JM Garcia De Veas Marquez (Madrid,ES), L Rodriguez Sotelo (Madrid,ES), FJ Irazusta Cordoba (Madrid,ES), A Castro Conde (Madrid,ES), JL Lopez Sendon Herschel (Madrid,ES)

Authors:
A Velez Salas1 , LA Martinez Marin1 , R Dalmau Gonzalez-Gallarza1 , A Rivas Perez1 , JM Garcia De Veas Marquez1 , L Rodriguez Sotelo1 , FJ Irazusta Cordoba1 , A Castro Conde1 , JL Lopez Sendon Herschel1 , 1University Hospital La Paz - Madrid - Spain ,

Citation:

Introduction: HDL cholesterol (HDLc) has an important role in atherosclerosis, with levels <40 mg/dl in men and <48mg/dl in women recognised as a cardiovascular risk factor. Nowadays there are many treatments available to LDL cholesterol, but HDLc management has a minor role in secondary prevention. Although statins and fibrates may increase its levels, lifestyle intervention and smoking cessation are the main therapeutic tools. Methods: retrospective analysis of patients that completed a cardiac rehabilitation program (CRP) after an acute coronary syndrome (ACS) between 2006 and 2016. We compared laboratory findings prior and after CRP. The aim was to analyse the profile of the patients with low HDL, their level evolution and the factors that could explain very low levels of HDL (<30 mg/dl) after CRP. Results: we included 1250 patients, of which 18.7% had very low levels of HDLc. These were predominantly male (94.7%, p<0.01), had a higher proportion of diabetes mellitus (35.1%, p<0.01) and overweigh (BMI>25 79.4%, abdominal perimeter 102.1 ± 11.7, p<0.01) and also had lower levels of LDLc, and higher values of HbA1c (6.4 ± 1,5, p<0.01). After completing CRP, 517 patients (37.2%) had a higher HDL levels, and this improvement was more frequent in women (18.2%, p = 0.03) and in those who stopped smoking (60.7%, p <0.01). Conclusion: the role of HDLc as a cardiovascular risk factor is probably underestimated, since it is very frequent in patients with ACS. Currently its treatment is based on lifestyle intervention, but in many cases HDLc does not improve despite CRP. The question now is whether low HDL must be contemplated only as a marker of risk, or if it should be considered as a therapeutic target.

Group 1: HDL>30 (N = 968)

Group 2: HDL<30 (N = 246)

P value

Age

57.9 ± 10.8

56.2± 10.1

0.02

Sex (male)

791 (81.7%)

233 (94.7%)

<0.01

Hypertension

466 (48.1%)

134 (54.9%)

NS

Diabetes mellitus

220 (23%)

86 (35.1%)

<0.01

Active smoker

502 (54.6%)

139 (57.9%)

NS

Abdominal perimeter

99.1 ± 11.4

102.1 ± 11.7

<0.01

BMI>25

678 (70.5%)

193 (79.4%)

<0.01

LDLc

114.1 ± 39.9

97.55 ± 34.4

<0.01

LDLc after CRP

72 ± 24.7

67.3 ± 28.3

0.01

HbA1c

5.9 ± 1.2

6.4 ± 1,5

<0.01

HbA1c after CRP

5.8 ± 0.7

5.9 ± 0.9

0.01



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are